**S2 Text. List of excluded studies from the review**

1. Churchyard GJ, Fielding KL, Lewis JJ, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014;370:301-310
2. Fitzgerald 2000: Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD, Pape JW. [Effect of post treatment isoniazid on prevention of recurrent tuberculosis in HIV–1 infected indivduals: a randomized trial]. The Lancet 2000;356: 1470–1474.
3. Garcia 1993: GraciaML, Valdespino JL, Garcia-SanchoC,Weissenbacher M, Daniels E, Peruga A, Palacios M, Loo E, Cruz C, LinaJL, Luna M, Mayar ME, Romero C, Pineda L, Sepulveda J. Compliance and side effects to chemoprophylaxis for TB in HIV+. Mexican experience. IX International Conference on AIDS. 1993; Vol. Abstract–Po–BO7–11.
4. Gordin 2000: Gordin F, Chaisson RE, Matts JP, et al.Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-Infected persons. An international randomized trial. *JAMA* 2000;283:1445–1450.
5. Grant 2005*:* Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, De Cock KM, Hayes RJ, Churchyard GJ. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental study. *JAMA* 2005; 293(22):2719–2725.
6. Halsey 1998:Halsey NE, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, ContaveM, Johnson M, Davis H, Geitre L, Johnson E, Huebner R, Boulos R, Chaisson R. Randomized trial of isoniazid versus rifampicine and pyrazinamide for prevention of tuberculosis in HIV-1 infection. *The Lancet* 1998;351(9105):786–792.
7. Lim HJ, Okwera A, Mayanja-Kizza H, Ellner JJ, Mugerwa RD, Whalen CC. Effect of Tuberculosis Preventive Therapy on HIV Disease Progression and Survival in HIV-Infected Adults. HIV clinical trials. 2006;7(4):172-183. doi:10.1310/hct0704-172.
8. Martinez 2000:Martinez AEM, Cuadra F, Solera J, Macia MA, Geijo P, Sanchez MPA, Rodriguez ZM, Largo J, Sepilveda MA, Rosa C, Sanchez L, Espinosa A, Mateos F, Blanch JJ. Evaluation of 2 tuberculosis chemoprohylaxis regimens in patients infected with human immunodeficiency virus. The Gecmei Group. *Medicina Clinica (Barcelona)* 2000;115(5): 161–165.
9. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20
10. Matteelli 1998*:* Matteelli A, Carosi G, Signorini L, Tebaldi A, Caligaris S, Gulletta M. Multinational study for preventive therapy of latent tuberculosis in HIV positive individuals: isoniazid vs. rifabutin. 12th World AIDS Conference. 1998; Vol. Abstract 60858.
11. Rivero 2007: Rivero A, López-Cortés L, Castillo R, Verdejo J, García MA, Martínez-Marcos FJ, Díez F, Escribano JC, Canueto J, Lozano F, Pasquau J, Hernández JJ, Márquez M, Kindelán JM. A Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients. Enferm Infecc Microbiol Clin 2007;25(5):305–310.
12. Saenghirunvatta 1996*:* Saenghirunvattana S. [Effect of isoniazid prophylaxis on incidence of active uberculosis among Thai HIV–infected individuals]. *J. Med Association Thai* 1996;79(5):285–287.
13. Souza, Claudia Teresa Vieira de et al. Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro. Mem. Inst. Oswaldo Cruz [online]. 2009, vol.104, n.3, pp. 462-467.
14. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-2166
15. Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, et al. (2012) Efficacy of a Six-Month versus a 36-Month Regimen for Prevention of Tuberculosis in HIV-Infected Persons in India: A Randomized Clinical Trial. PLoS ONE 7(12): e47400. doi:10.1371/journal.pone.0047400